Please try another search
Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States. The company focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. Its products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial. The company was formerly known as Ruenvex Biotech, Inc. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
Name | Age | Since | Title |
---|---|---|---|
Allen Y. Chao | 78 | 2013 | Honorary Chairman |
Jin-Pau Tsai | - | 2015 | Independent Director |
Chi-Chuan Chen | 66 | 2013 | Director |
David C. Hsia | 79 | 2015 | Director |
Tamon Tseng | - | 2013 | Director |
Tay-Chang Wang | - | 2021 | Independent Director |
Jang-Yang Chang | - | 2022 | Independent Director |
Lin-Cheng Chen | 53 | 2023 | Chairman & CEO |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review